Callisto Outlines Achievements in Development of Anti-Cancer Drug Candidates and Other Recent Advances in Online Interview
Thursday December 8, 3:30 am ET
CEO Dr. Gary Jacob Discusses Latest Clinical Milestones and Strategic Initiatives with Wall Street Reporter
NEW YORK--(BUSINESS WIRE)--Dec. 8, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL - News; FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today announced the availability of a streaming audio interview given by CEO and Chief Scientific Officer Dr. Gary S. Jacob to the online investor news and information source, the Wall Street Reporter.
In the interview, Dr. Jacob outlines the Company's scientific achievements and its multi-pronged R&D program.
Callisto's drug development pipeline and intellectual property portfolio currently includes new drugs in development for the blood cancers leukemia and multiple myeloma, as well as a biodefense program to develop vaccines for the Homeland Security marketplace, and a proprietary breakthrough drug candidate for a variety of serious gastro-intestinal conditions.
Callisto's drugs Atiprimod and L-Annamycin are currently in clinical trials, and are being developed as treatments for patients with relapsed cases of
multiple myeloma and
acute leukemias,
respectively.
L-Annamycin and Atiprimod could eventually provide a new clinical standard of care for relapsed patients whose cancers don't respond under the currently available regimens, Dr. Jacob says in the interview. He also notes that Atiprimod recently was recognized by the scientific research community: two separate research abstracts on the drug were selected as the subject of high-profile oral presentations for delivery, and one abstract was selected as a poster presentation later this week at the prestigious, high-profile annual meeting of the American Society of Hematology in Atlanta, Ga., Dec. 10-13.
In addition, Dr. Jacob discusses the Company's development of a proprietary drug to treat ulcerative colitis and other serious gastro-intestinal conditions, and that may serve as a preventative therapy for colon cancer. He also provides details of Callisto's homeland defense initiative, the Superantigen Biodefense Project, which is exploring development of a drug and vaccine to protect against biowarfare agents from the class of Staphylococcus and Streptococcus pathogens, with the aid of a major development grant from the National Institute of Allergy and Infectious Diseases.
The interview is available online and free of charge by visiting: wallstreetreporter.com, and clicking on the Callisto Pharmaceuticals link on the right side of the page.
About Wall Street Reporter
Wall Street Reporter is an acclaimed weekly news magazine read by fund managers, analysts, investment bankers, venture capitalists and influential members of the news media around the world. Institutional investors turn to Wall Street Reporter's timely features and interviews for insight into industry trends and to discover new investment opportunities. The Wall Street Reporter website is www.wallstreetreporter.com.
About Callisto Pharmaceuticals, Inc.
Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered Phase I/IIa human clinical trials in relapsed multiple myeloma patients. Callisto also has drugs in preclinical development for gastro-intestinal inflammation, and a program focused on the development of a drug to protect against Staphylococcus and Streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit trilogy-capital.com. For an Investor Fact Sheet about Callisto, please visit trilogy-capital.com. To view an informational presentation of the Company's development pipeline of drug candidates, visit trilogy-capital.com. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit www.callistopharma.com.
Forward-Looking Statements
Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K/A for the year ended December 31, 2004, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.
Contact:
Callisto Pharmaceuticals, Inc.
Dan D'Agostino, 212-297-0010 x227
dagostino@callistopharma.com
or
Trilogy Capital Partners, Inc.
Paul Karon, 800-592-6067 (Financial Communications)
paul@trilogy-capital.com
biz.yahoo.com |
